Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Yamanouchi prepares and tests new vasopressin V2 ligands

June 25, 2003

Extended-release alfuzosin approved for BPH

June 18, 2003

Long-term efficacy and safety results reported for lanthanum carbonate in chronic renal failure

June 17, 2003

Positive phase III topline results for Alprox-TD

June 17, 2003

Two series of ALK5 kinase inhibitors and their use described by GSK team

June 12, 2003

Ortho-McNeil scientists prepare and test novel PDE5 inhibitors

June 12, 2003

New PDE5 inhibitors in Schering-Plough development pipeline

June 11, 2003

Intranasal apomorphine enters new phase II study in erectile dysfunction

June 6, 2003

Influence of sildenafil on duodenal function and cirrhotic portal hemodynamics

June 4, 2003

Topiglan enters new phase II study for erectile dysfunction

June 4, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...